The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis
Simon Ekman, Murry W. Wynes, Fred R. Hirsch · Journal of Thoracic Oncology · 2012
Cited by 85 works. doi:10.1097/jto.0b013e31825581bd
Authors
References
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
- Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
- The AMP-activated protein kinase pathway – new players upstream and downstream
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
- eIF4E – from translation to transformation
- A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
- Mammalian target of rapamycin: a central node of complex signaling cascades.
- Epidermal Growth Factor and Hypoxia-induced Expression of CXC Chemokine Receptor 4 on Non-small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1α